Company Overview and News

Boustead Plantations eyes more land in Sabah

Lodin: Once again, we will be able to benefit from greater economies of scale as a result of the proximity of these estates to our existing estates in Sabah

Boustead Plantations to hive off ‘non-performing’ assets

Lodin: Our focus at the present moment is to develop our land in the Klang Valley and Johor.

Boustead Plantations net profit jumps on land sale

Tan Sri Lodin Wok Kamaruddin envisaged that CPO prices would soften as a result of rising palm oil production, which was projected to outpace consumption.

Trading ideas: PA Resources, Boustead Plantations, Econpile, Gadang

KUALA LUMPUR: JF Apex Research expects P.A Resources Bhd, Boustead Plantations , Econpile Holdings Bhd and Gadang Holdings Bhd to be among the stocks to watch on Thursday.

Boustead sells land for RM136mil

It will continue to own and operate its plantation business on the remaining 1,389 acres of the Malakoff Estate.

Boustead Plantations reaps RM116mil gain from Penang land sale

KUALA LUMPUR: Boustead Plantations Bhd is selling part of its oil palm estate in Penang for RM136mil cash, reaping a huge profit that the company said it will use to repay loans taken for acquisition of new plantation land.

Debt raising vital for Khazanah stable of enterprises

Power funding: TN B has the most amount of debt at RM21.6bil given the expensive nature and demands for funding power stations. — Reuters

Trading ideas: IJM, Gabungan AQRS, Hock Seng Lee, Sime Darby

KUALA lUMPUR: IJM Corp Bhd , Gabungan AQRS Bhd , Hock Seng Lee and Sime Darby are among the stocks to watch on Wednesday, according to JF Apex Research.

Boustead Plantations Q3 earnings jump, declares 10c dividends

Boustead Plantations vice chairman Tan Sri Lodin Wok Kamaruddin said the nine-month financial results were due to gains realised from disposal of land while earnings were supported by better selling prices for palm products.

DutaLand has one year to identify new business

Yap: Just wait until the next extraordinary general meeting to get more details on the potential new businesses.

Breakfast briefing: Wednesday, November 1

MarketWatch: A jump in shares of consumer companies Mondelez and Kellogg after their quarterly reports on Tuesday, along with further gains for tech stocks, helped Wall Street end October on a positive note. The DJIA rose 28.5 points, or 0.12%, to 23,377.24, the S&P 500 gained 2.43 points, or 0.09%, to 2,575.26 and the Nasdaq Composite added 28.71 points, or 0.43%, to 6,727.67. - Reuters

Sabah estates purchase expensive, say analysts

Analysts said this adding that in the near term, Boustead Plantations would need to monetise more of its estates in Peninsular Malaysia to supplement its income and sustain its dividend payouts.

Breakfast briefing: Tuesday, October 31

MarketWatch: Wall Street pulled back from record-high territory on Monday, weighed down by a drop in Merck shares and a report that US lawmakers are discussing a gradual phase-in of much-anticipated corporate tax cuts. The DJIA fell 85.45 points, or 0.36%, to 23,348.74, the S&P 500 lost 8.24 points, or 0.32%, to 2,572.83 and the Nasdaq dropped 2.30 points, or 0.03%, to 6,698.96. - Reuters

Boustead to invest RM250mil to boost Sabah estates’ yield

The Boustead Plantations group operates 13 estates and four palm oil mills in Sabah, with a total plantation land of 29,482ha. Their yield, at 16.6 tonnes per ha last year, is more than double that of the estates being acquired from DutaLand.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...